Abcam Past Earnings Performance
Past criteria checks 0/6
Abcam's earnings have been declining at an average annual rate of -48.6%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 9.3% per year.
Key information
-48.6%
Earnings growth rate
-49.5%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 9.3% |
| Return on equity | -1.2% |
| Net Margin | -2.4% |
| Next Earnings Update | 31 Aug 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Abcam makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 362 | -8 | 184 | 35 |
| 30 Sep 22 | 356 | -1 | 181 | 33 |
| 30 Jun 22 | 350 | 7 | 178 | 32 |
| 31 Mar 22 | 333 | 6 | 167 | 28 |
| 31 Dec 21 | 315 | 4 | 157 | 24 |
| 30 Jun 21 | 298 | 16 | 153 | 25 |
| 31 Mar 21 | 284 | 7 | 144 | 23 |
| 31 Dec 20 | 295 | 26 | 147 | 27 |
| 30 Sep 20 | 265 | 5 | 125 | 20 |
| 30 Jun 20 | 260 | 13 | 132 | 38 |
| 31 Mar 20 | 267 | 27 | 121 | 22 |
| 31 Dec 19 | 273 | 43 | 102 | 12 |
| 30 Sep 19 | 267 | 44 | 96 | 11 |
| 30 Jun 19 | 260 | 44 | 96 | 15 |
| 31 Mar 19 | 253 | 51 | 89 | 12 |
| 31 Dec 18 | 245 | 58 | 88 | 14 |
| 30 Sep 18 | 239 | 60 | 83 | 15 |
| 30 Jun 18 | 233 | 62 | 78 | 16 |
| 31 Mar 18 | 230 | 59 | 79 | 18 |
| 31 Dec 17 | 227 | 55 | 81 | 19 |
| 30 Sep 17 | 222 | 49 | 80 | 19 |
| 30 Jun 17 | 217 | 42 | 79 | 19 |
| 31 Mar 17 | 206 | 41 | 72 | 18 |
| 31 Dec 16 | 196 | 40 | 66 | 17 |
| 30 Sep 16 | 184 | 39 | 63 | 16 |
| 30 Jun 16 | 172 | 37 | 59 | 14 |
Quality Earnings: ABCM N is currently unprofitable.
Growing Profit Margin: ABCM N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABCM N is unprofitable, and losses have increased over the past 5 years at a rate of 48.6% per year.
Accelerating Growth: Unable to compare ABCM N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABCM N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Return on Equity
High ROE: ABCM N has a negative Return on Equity (-1.17%), as it is currently unprofitable.